ArticleMilitary Medical Research2025
Identification of the lymph node metastasis atlas and optimal lymph node dissection strategy in patients with resectable lung invasive mucinous adenocarcinoma: a real-world multicenter study.
Article in Military Medical Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hybrid Deep Learning-Machine Learning Fusion of Clinical, Radiomic and Deep Learning Features for Preoperative Differentiation of Solitary Pulmonary Mucinous Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung invasive mucinous adenocarcinoma (LIMA) is a rare, unique, and heterogeneous subtype of lung cancer whose patterns of lymph node (LN) metastasis are unknown, and a consensus on LN dissection (LND) has not been reached. This study aimed to evaluate LN metastasis patterns in LIMAs and establish optimal LND strategies.
methodsData about 19,596 LNs from 1474 LIMA patients collected between January 2010 and December 2021 at 8 lung cancer research centers and tertiary hospitals across China, and data from 5304 LIMA patients between 2004 and 2021 in the SEER database were analysed. Metastasis probabilities were calculated for each LN station to construct a metastasis atlas. Statistical methods, including LOWESS fitting, restricted cubic spline, Kaplan-Meier, and logistic regression analyses, were employed to identify optimal LND strategies.
resultsCompared with non-mucinous adenocarcinoma patients, LIMA patients exhibited distinct clinicopathological features and a significantly lower probability of LN metastasis (4.20% vs. 7.19%, P < 0.05). Metastasis was most common in the peripheral and hilar/interlobar zones (especially stations 14 and 10), with minimal involvement in the lower zone (stations 8 and 9). A U-shaped relationship between the LN count and prognosis (including overall survival, relapse-free survival, and cancer-specific survival) was found, with 6-20 and 18 LNs as the optimal range and cut-off point, respectively. Excessive or insufficient dissection was linked to poorer outcomes. A predictive model (area under the receiver operating characteristic cure = 0.8367) revealed that patients with a probability ≥ 0.5 had a significantly greater proportion of patients with stage N1+ disease (including N1 and N2 patients) (68.09% vs. 11.63%, P < 0.001) and worse overall survival [hazard ratio (HR) = 4.00, 95% CI 2.72-5.87, P < 0.001] and relapse-free survival (HR = 5.53, 95% CI 3.97-7.71, P < 0.001). The minimum numbers of LNs for the low- (probability < 0.1), medium- (probability 0.1-0.5), and high- (probability > 0.5) risk patients were 7, 14, and 17, respectively. For those with uncertain metastatic risk, dissecting 18 LNs may be the most appropriate and robust strategy.
conclusionsThis study systematically revealed the pattern of LIMA-specific LN metastasis and proposed a risk-stratified LND strategy. These recommendations balance the imperatives of accurate staging with the preservation of long-term patient prognosis, offering a practical guideline for surgical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.